Articles dans des revues avec comité de lecture (142)
  1. 58. moretti, M., Allard, S. D., Dauby, N., De Geyter, D., Mahadeb, B., Miendje Deyi, Y. V., Balti, E. E., & Clevenbergh, P. A. (2021). Clinical features of Legionnaires’ disease at three Belgian university hospitals, a retrospective study. Acta Clinica Belgica (English ed. Printed), 1-7. doi:10.1080/17843286.2021.1978211
  2. 59. Montesinos Hernandez, I., Dahma, H., Wolff, F., Dauby, N., Delaunoy, S., Wuyts, M., Detemmerman, C., Duterme, C., Vandenberg, O., Martin, C., & Hallin, M. (2021). Neutralizing antibody responses following natural SARS-CoV-2 infection: dynamics and correlation with commercial serologic tests. Journal of clinical virology, 104988. doi:10.1016/j.jcv.2021.104988
  3. 60. Bastard, P., Dauby, N., Goffard, J.-C., Vandernoot, I., et al. (2021). Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Science immunology, 6(62), eabl4340. doi:10.1126/sciimmunol.abl4340
  4. 61. Asano, T., Dauby, N., et al. (2021). X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Science immunology, 6(62), eabl4348. doi:10.1126/sciimmunol.abl4348
  5. 62. Devos, T., Van Thillo, Q., Compernolle, V., Najdovski, T., Romano, M., Dauby, N., Jadot, L., Leys, M., Maillart, E., Loof, S., Seyler, L., Moonen, M., Moutschen, M., Van Regenmortel, N., Ariën, K. K., Barbezange, C., Betrains, A., Garigliany, M., Engelen, M., Gyselinck, I., Maes, P., Schauwvlieghe, A., Liesenborghs, L., Belmans, A., Verhamme, P., & Meyfroidt, G. (2021). Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. The European respiratory journal, 2101724. doi:10.1183/13993003.01724-2021
  6. 63. Gobert, C., Semaille, P., Van der Schueren, T., Verger, P., & Dauby, N. (2021). Prevalence and determinants of vaccine hesitancy and vaccines recommendation discrepancies among general practitioners in french-speaking parts of Belgium. Vaccines, 9(7), 771. doi:10.3390/vaccines9070771
  7. 64. El-Sokkary, R., Uysal, S., Erdem, H., Kullar, R., Pekok, A. U., Amer, F., Grgić, S., Carevic, B., El-Kholy, A., Liskova, A., Özdemir, M., Khan, E. A., Uygun-Kizmaz, Y., Pandak, N., Pandya, N., Arapović, J., Karaali, R., Oztoprak, N., Petrov, M. M., Alabadla, R., Alay, H., Kholy, J. A. E., Landelle, C., Khedr, R., Mamtora, D., Dragovac, G., Fernandez, R., Evren, E. U., Raka, L., Cascio, A., Dauby, N., Oncul, A., Balin, S. O., Cag, Y., Dirani, N., Dogan, M., Dumitru, I. M., Gad, M. A., Darazam, I. A., Naghili, B., Del Vecchio, R. F., Licker, M., Marino, A., Akhtar, N., Kamal, M., Angioni, G., Medić, D., Esmaoğlu, A., Gergely, S. B., Silva-Pinto, A., Santos, L., Miftode, I. L., Tekin, R., Wongsurakiat, P., Khan, M. A., Kurekci, Y., Pilli, H. P., Grozdanovski, K., Miftode, E., Baljic, R., Vahabolgu, H., & Rello, J. (2021). Profiles of multidrug-resistant organisms among patients with bacteremia in intensive care units: an international ID-IRI survey. European journal of clinical microbiology & infectious diseases. doi:10.1007/s10096-021-04288-1
  8. 65. Dauby, N. (2021). Impact sociétal de la vaccination : Au-delà de la protection individuelle Regain d'intérêt face à la pandémie COV ID-19 ? RMLG. Revue médicale de Liège, 75, 170-175.
  9. 66. Albayrak, N., Dirix, V., Aerts, L., Van Praet, A., Godefroid, A., Dauby, N., Windey, P., Muylle, I., Mascart, F., & Corbiere, V. (2021). Differential expression of maturation and activation markers on NK cells in patients with active and latent tuberculosis. Journal of leukocyte biology. doi:10.1002/JLB.4A1020-641RR
  10. 67. Dauby, N., & Martin, C. (2021). SARS-CoV-2 immunity and HIV infection: total recall? The Lancet HIV. doi:10.1016/S2352-3018(21)00097-7
  11. 68. Gobert, C., Van Hauwermeiren, C., Quoidbach, C., Reschner, A., Necsoi, C. V., Benslimane, A., Nagant, C., Van den Wijngaert, S., Delforge, M.-L., Corazza, F., De Wit, S., & Dauby, N. (2021). Tetanus seroprotection in people living with HIV: Risk factors for seronegativity, evaluation of medical history and a rapid dipstick test. Vaccine, 39(14), 1963-1967. doi:10.1016/j.vaccine.2021.02.062
  12. 69. Martin, C., Domingo, C., Bottieau, E., Buonfrate, D., De Wit, S., Van Laethem, Y., & Dauby, N. (2021). Immunogenicity and duration of protection after yellow fever vaccine in people living with HIV: A systematic review. Clinical microbiology and infection. doi:10.1016/j.cmi.2021.03.004
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Suivant >>